GSJ: Volume 10, Issue 2, February 2022, Online: ISSN 2320-9186
www.globalscientificjournal.com

DNA METHYLATION: AN EPIGENETIC BIOMARKER OF CARDIOVASCULAR DISEASES: A REVIEW

Miteu Goshen David[1], Adima Gloria Onwanyi[2], Iquo Oyohosuho Phillip[3], Adekale Idris Adediran[4,5], Aderanti Adedotun Afeez[6], Njoku Prisca Chinonso[7], Faniyi Akinwale John[8*], Olagunju Abolaji Samson[9]

1. **Department of Chemistry and Biochemistry, Caleb University Imota, Lagos, Nigeria; goshendavids@gmail.com ; miteu.goshen@calebuniversity.edu.ng**
2. **Department of Biological Sciences, Microbiology, Benue State University, Makurdi; adimaogloria@gmail.com**
3. **Department of Genetics and Biotechnology, University of Calabar; iquophillip@unical.edu.ng**
4. **Osun State University, Osogbo, Nigeria; idrisdiran@gmail.com**
5. **Bayero University, Kano, Nigeria; idrisdiran@gmail.com**
6. **Department of Medical Laboratory Science, Ladoke Akintola University of Technology, Nigeria**
7. **Department of Biochemistry, University of Lagos, Lagos, Nigeria priscanjoku0@gmail.com**
8. **Department of Medical Laboratory Sciences, Ladoke Akintola University of Technology, Ogbomoso, Nigeria. faniyiakinwale2014@gmail.com**
9. **Department of Biochemistry, Faculty of Basic Medical Sciences, University of Ibadan, Ibadan, Nigeria. abolajisamson05@gmail.com**

Corresponding author:

***- faniyiakinwale2014@gmail.com**

Abstract

Cardiovascular illnesses are the leading cause of death worldwide, and they have a significant influence on both qualities of life and healthcare expenses. An enormous amount of work has gone into research to develop new techniques for diagnosing and forecasting the prognosis of these diseases in a timely and efficient manner. Epigenetic pathways have been discovered, and they have been connected to the pathogenesis of various cardiovascular illnesses. This has consequences for disease progression and can help with treatment trials for new drug designs and prevention tactics. Advances in methodology and large-scale data analysis have identified novel components and targets linked to various diseases, allowing for more individualized epigenetic mapping for personalized diagnosis and treatment. This provides for pharmacogenetics, which anticipates pharmaceutical reactions and supports personalized treatment based on differences in each patient's epigenetic basis. DNA methylation has also emerged as a promising tool for the accurate detection and prediction of cardiovascular disorders. They are excellent for use in clinical practice because of their considerable openness and possible localization techniques. As a result, this review focuses on DNA methylation as an epigenetic biomarker for cardiovascular illnesses. It also aims to highlight how DNA methylation can enhance cardiovascular patient diagnosis, prognosis, and therapy.

Keywords: DNA methylation, epigenetics, biomarker, cardiovascular diseases, myocardial infarction, heart failure, atherosclerosis, hypertension

Introduction

Cardiovascular diseases (CVDs) are leading cause of death in developed countries. Hypertension, atherosclerosis, myocardial infarction (MI), ischemia/reperfusion injury, stroke, and heart failure (HF) are examples of cardiovascular illnesses that affect the architecture or functions of the heart and veins (Wang *et al*., 2016; Thomas *et al*., 2018). Mechanisms underlying the complicated pathophysiology that leads to CVDs are of great interest; however, they are far from clear. Epigenetics revolves around changes in gene expression caused by environmental variables or conditions. It is the component that aids the cell in reacting to environmental changes, thereby establishing a link between the gene and the environment. The environmental conditions to which one is exposed might create differences in quality articulation independent of DNA succession and development as a result of the epigenetic system. This elucidates how the cell reacts to external elements such as pressure, stress, pollution, contamination, smoking, and diet.



Figure 1: DNA methylation and epigenetics (Costantino *et al*., 2018).

There are controversies on how the interaction of hereditary and environmental factors contributes to the development of cardiovascular disease (CVD). Epigenetics may provide a better understanding of the cardiovascular effects of these collaborations, as recent research on epigenetic pathways has linked hereditary and environmental factors (Bacarelli *et al*., 2010). Epigenetics, or heritable atomic changes, and its related aggregates, which do not include changes in DNA arrangement (Padmanabhan and Joe 2017), but rather instruments such as DNA methylation, histone alteration, and post-transcriptional silencing intervened by miniature RNAs, are examples of epigenetics (micro RNAs). Epigenetics is an acquired component that contributes to the onset of most CVDs since these alterations or changes are heritable and can be transmitted through mitosis or meiosis (Padmanabhan and Joe 2017). DNA methylation is the best studied of these changes compared to the cardiovascular framework because it can be quantified in an epidemiological setting (Michels, 2012). DNA methylation is defined by genetic and environmental factors because environmental factors can influence methylation (Rau and Vondriska 2017).

DNA methylation is an essential epigenetic component and a quality articulation controller, implying that it is a promising biomarker for cardiovascular disorders - a disease that has claimed many lives throughout the world. The majority of the genes for instance AAA are linked

to cardiovascular infections are controlled by epigenetic mechanisms, which means that any modification (such as DNA methylation) significantly impacts the risk of cardiovascular disease (Thom *et al*., 2016).

In light of the function of genetics and its environmental linkage in diseased cases, advances in the field of epigenetics have opened up a new universe for the perception and control of human infections, including the preponderance of CVDs. Colossal evidence suggests that the environment and style of living can influence epigenetic designs throughout one's life. These epigenetic patterns represent a cell's memory of additional exposure to the environment. Epigenetic changes are reversible, unique to different cell types, and can potentially increase susceptibility by causing long-term changes in gene transcription (Beekman *et al*., 2010).

The process of DNA methylation involves the addition of a chemical group to DNA. This group is added to precise locations on DNA regularly, preventing the proteins that attach to DNA from "reading" the gene. Demethylation is a chemical reaction that can be used to remove this chemical group. DNA methylation often occurs in mammals at the fifth carbon of cytosine nucleotides located inside CG dinucleotides, referred to as CpG locales, found across the genome in genic and intergenic areas (Raghuraman *et al*., 2016). (Gillette and Slope, 2015; Yang *et al*.,2018)

EPIGENETIC MECHANISMS

Epigenetic processes involve the modification of gene expression. The gene activity from such modification is passed from one generation of cells to another providing another process of inheritance and variation (Lind and Spagopoulou, 2018). Epigenetic mechanism is divided into three:

i. Non-coding RNAs (lncRNAs) and microRNAs (miRNAs): This mechanism was recently recognized. Non-coding RNAs (ncRNAs) are functional RNA transcripts that are not translated into protein. They are classified into small ncRNAs which are <200 base pairs (bp) for example microRNAs (miRNAs) and short-interfering or silencing RNAs (siRNAs) or long ncRNAs (lncRNAs) which are >200 bp in length (Boon et al. 2016). DNA methylation and histone modifications are important for miRNA regulation in various types of cancer (Ahmad et al. 2014) and miRNAs regulate multiple cellular functions involved in atherosclerosis such as oxidative stress, cholesterol metabolism and endothelial dysfunction (Schober and Weber 2016).

ii. Histone modification: Histone modification involves post translational modifications such as acetylation, methylation, ubiquitination and phosphorylation of histone proteins.

These mechanisms are important in the regulation of chromatin structure and gene expression by modulating the degree of chromatin compaction (Bannister and Kouzarides 2011). The enzymes involved in histone modifications act at at histone N-terminal tails primarily involving the amino acids lysine (K) and arginine (R). These modifications can elicit transcriptional activation or repression as they are present on multiple but specific sites on the histones and integrated into upstream signaling pathways (Kouzarides 2007).

iii. DNA methylation: This is the most basic and common epigenetic mechanism. It involves the covalent addition of a methyl group to a cytosine at a cytosine linked to guanine by a phosphate group (5'-C-p-G-3'; CpG site) (Holliday and Pugh 1975). Cytosines are methylated to 5-methylcytosine (5mC). This is catalyzed by a group of enzymes known as DNA methyltransferases (DNMTs); DNMT1, DNMT3A, DNMT3B. The DNA methyl-binding proteins (MBPs) recognizes the methylation of cytosine. Another mechanism is DNA hydroxymethylation which involves 5-hydroxymethylated cytosines (5hmC). The oxidation of 5mC to 5hmC is catalyzed by a group of enzymes called the ten-eleven translocation (TET) enzymes (TET1, TET2, TET3). These enzymes can also further catalyze conversion to 5-formylcytosine (5fC) and 5-carboxylcytosine which can then be replaced by unmethylated cytosine through the action of thymine DNA glycosylase (TDG)-mediated base excision repair (Branco *et al*. 2011; Dimple *et al*., 2019). This review will be focused on DNA methylation and its role in cardiovascular diseases.



Figure 2: The three main epigenetic mechanism (Dimple *et al*., 2019).

Epigenetics and DNA methylation

Chromatin alterations, such as DNA methylation, results in the exchange of a methyl group to carbon 5 of the cytosine buildups [5-methylcytosine (5mC)] in DNA (Baccarelli *et al*., 2010 ; Costantino *et al*., 2018).

Methylation occurs at the lysine or arginine buildups and can start or stop quality records depending on the methylation level, and which advertisement is methylated (Li *et al*., 2017c; Sabia *et al*., 2017). Protein kinases and phosphatases can phosphorylate and dephosphorylate the serine, threonine, and tyrosine buildups of histone tails, respectively.

Epigenetic alterations and DNA methylation play a critical role in the progression of pathological disorders, including CVDs, due to their enormous capacity in gene regulation.

In most cases, DNA methylation at the CpG Island silences a gene by preventing transcription enzyme complexes from binding to their respective target gene promoters. DNA methylation at

this region can also promote the binding of methylases to their respective target gene promoters (Jeltsch & Jurkowska, 2014).

Methylation of DNA in CVD

Changes in DNA methylation have been linked to the underlying risk factors of CVD, such as atherosclerosis, hypertension, and inflammation (Baccarelli *et al*., 2010). For example, mice with a hypomethylated genome had higher levels of inflammatory markers, and DNA hypomethylation was shown to occur before the formation of an aortic fatty streak (Movassagh *et al*., 2010).

Cardiovascular epigenetics research has accelerated in recent years, moving from biological and animal studies to epidemiological investigations. Methylation of repetitive sequences in blood, such as long-interspersed nucleotide repetitive elements-1 (LINE-1) and ALU, has been linked to CVD (Baccarelli *et al*., 2010; Kim *et al*., 2010). Elevated methylation of ALU in leukocytes has been linked to CVD and obesity in Chinese people (Kim *et al*., 2010). (Movassagh *et al*., 2011). DNA methylation in the GNAS antisense RNA 1 (GNASAS1) and insulin (INS) genes, both of which have previously been linked to prenatal nutrition, has been linked to a three-year risk of myocardial infarction in older women (Talens *et al*., 2012). Furthermore, DNA isolated from atherosclerotic tissue was hypomethylated in general but hypermethylated in the promoter regions of genes linked to atherosclerosis (Ordovăs and Smith, 2010).

Understanding the hidden heart abnormalities caused by epigenetic and how these epigenetic instruments can be used in diagnosis (i.e., biomarkers) and treatments is critical to improving patient condition. A biomarker is a quantifiable hallmark in medicine that reflects a specific physiological or psychological condition or a reaction to a therapy (Strimbu and Tavel, 2010). Biomarkers should ideally be simple to use, have a conspicuous location, and be consistent (Sun *et al*., 2017). It is required to create a specific quantitative alteration that is linked to a conclusion or expected consequence. In this way, biomarkers provide information to doctors when determining the likelihood of developing a disease, drawing conclusions, assessing the seriousness of an infection and its progression; during the remedial process; or checking a patient's reaction, and may result in significant cost savings (Baccarelli *et al*., 2010). Their classification might be based on their use (inclination, conclusion, checking, wellbeing, prognostic, or prescient biomarkers). Inclination biomarkers determine how likely a patient is to get a specific ailment. They are commonly utilized when an individual or family lineage demonstrates an infection risk, and the results can help orient clinical care. Symptomatic biomarkers are used to detect or confirm the presence of a health disease, and they may aid in its

early detection. Biomarkers are used to assess an infection's severity or determine whether or not someone is open to working with an ecological specialist or a clinical item. Biomarkers for health show the possibility, existence, or degree of toxicity of a given clinical item or environmental specialty. Prognostic indicators explain how an illness might progress in those who are already suffering from it. Although these biomarkers do not predict therapy response, they can help select patients for treatment. Patients who are on their way to having a favorable or unfavorable reaction to a medication can be identified using predictive biomarkers. As a result, they can predict therapeutic success or adverse side effects in a particular patient. Patients with the same ailment may have different natural components. Predictive biomarkers can be linked to the specific system of a health problem. This works in conjunction with a targeted treatment, which employs medications specifically designed to treat a particular organic instrument linked to a disease, increasing its efficacy (FDA-NIH Biomarker Working Gathering, 2016). This survey focuses on epigenetic biomarkers that have a place with the great majority of these orders, focusing on CVDs. This review provides an overview of current research on epigenetic biomarkers in CVDs and how this information might help with cardiovascular patient diagnosis, prediction, and treatment.

Cardiovascular diseases and DNA methylation

Hypertension

Hypertension is a complex disease with few component and metabolic frameworks linked to its pathophysiology. Changes in numerous pathways such as AAA may be triggered by genetic and environmental variables, leading to the disease. Intrauterine changes, such as poor health, malnutrition, stoutness, booze, drugs, nicotine, or environmental pollutants, are among the environmental factors linked to the development of hypertension in the child (Franceschini and Le, 2014). This has a considerable impact on CVD hazard factor management and is a non-pharmacological treatment strategy. Hypermethylation of genes, such as superoxide dismutase-2 (SOD2) or Granulysin, or increased degrees of histone acetylation at the promoter of the endothelial oxide synthetase gene (eNOS), are also epigenetic variables that can influence the prevalence of hypertension in adults (Wang *et al*., 2018b). Environmental variables have an essential role in determining a person's propensity for developing significant cardiovascular risk factors through epigenetic changes (Franceschini and Le, 2014). Identifying epigenetic components involved in hypertension improvement could aid in the development of new

treatments. This is of great relevance because hypertension is a significant risk factor for CVDs such as MI, heart failure, stroke, and end-stage renal disease.

Hypertension is caused by a lack of mobility of the 11 beta-hydroxysteroid dehydrogenases 2 (HSD11B2). The HSD11B2 promoter was unusually methylated in patients with primary hypertension or glucocorticoid-induced hypertension. These patterns could reflect a global trend, with methylation of the gene promoter being a potentially helpful atomic biomarker for identifying hypertension patients (Alikhani-Koopaei *et al*., 2004; Friso *et al*., 2008). A mutation in the disruptor of telomeric hushing one gene (DOT1L), which encodes a methyltransferase that upgrades methylation of histone 3 (H3K79) in the promoter of the renal epithelial sodium channel gene (ENaC), has also been linked to circulatory strain guideline (Duarte *et al*., 2012). A DOT1A and ALL1 (intertwined gene from chromosome 9 [Af9]) collaboration has also been linked to H3K79 hypermethylation of the ENaC promoter, suffocating its transcriptional activity. This relationship is disrupted by aldosterone, which causes hypomethylation of H3K79 at specific locations, preventing the ENaC promoter from being restrained and causing hypertension. As a result, the Dot1a-Af9 pathway could be involved in regulating genes linked to hypertension (Zhang *et al*., 2009). Hypomethylation of the promoter of the -adducin gene (ADD1) has been linked to the risk of primary hypertension. Despite this, differences between males and females have been identified (Zhang *et al*., 2013a). In addition, lysine-explicit demethylase-1 (LSD1) causes histone 3 (H3K4 or H3K9) demethylation, affecting gene expression. In heterozygous LSD1 mutant mice fed a high-salt diet, hypermethylation of histone three was linked to hypertension, increased vascular constriction, and decreased unwinding via the nitric oxide-cGMP (NO-cGMP) pathway (Pojoga *et al*., 2011). Histone deacetylation has also been linked to a reduction in aspiratory blood vessel hypertension.

Protein levels of HDAC1 and HDAC5 are elevated in the lungs of patients and hypoxic rodents. In rodents, inhibiting these proteins with valproic corrosive and suberoylanilide hydroxamic corrosive slowed the progression of hypoxia-induced aspiratory hypertension. HDAC1 and HDAC5 levels could thus be helpful predictive indicators for managing patients with pneumonic hypertension (Zhao*et al*., 2012).

Atherosclerosis

Atherosclerosis is a chronic infection characterized by the accumulation of cholesterol in the dividers of large and medium-sized veins, the accumulation of extracellular framework and lipids, and the development of smooth muscle cells. This cycle results in the entry of resistant cells (primarily macrophages) and endothelial breakdown, generating a plaque and eventually

leading to serious cardiovascular events such as MI, peripheral vascular disease, aneurysms, and stroke. Low-density lipoprotein (LDL) cholesterol and oxidized LDL cholesterol have been proposed to stimulate a long-term epigenetic reorganization of natural invulnerable framework cells. Even after removing atherosclerotic improvements, this prompts a constant enactment (Bekkering *et al*., 2016). The growing body of evidence supports epigenetic changes being linked to the onset and progression of atherosclerosis, playing a pivotal role in plaque improvement and weakening, and emphasizing the importance of epigenetic biomarkers as CVD indicators (Xu *et al*., 2018).

Atherosclerosis is also linked to DNA methylation. Valencia-Spirits *et al*. (2015) used DNA methylation microarrays to identify CpG methylation profiles in the progression of atherosclerosis in the human aorta.Atherosclerosis is also linked to DNA methylation. Valencia-Spirits *et al*. (2015) used DNA methylation microarrays to identify CpG methylation profiles in the progression of atherosclerosis in the human aorta. They discovered a link between histologic pathology and the differential methylation of numerous autosomal traits in vascular tissue, which led to discovering biomarkers for harm severity and therapeutic genes (Valencia-Spirits *et al*., 2015). Drosophila headcase (HECA), early B-cell factor 1 (EBF1), and nucleotide-restricting oligomerization space containing 2 (NOD2) are all hypomethylated in atheromatous plaque injuries, whereas mitogen-enacted protein kinase 4 (MAP4K4), zinc finger E-box restricting homeobox 1 (ZEB1), and proto-oncogene tyrosine-protein kinase ((Yamada *et al*., 2014).

Acute Myocardial Infarction (AMI)

Acute MI (AMI) is a crippling illness that affects people all over the world. For ensured clinical mediation and further refined anticipation, early and exact differential discovery is essential (Reed *et al*., 2017). In particular, patients with ST-portion rising MI (STEMI) have unique requirements compared to those with non-STEMI (NSTEMI). Reperfusion treatment should be controlled quickly in the first gathering to reduce infarct size and mortality (Creators/Team people *et al*., 2014). Nonetheless, revascularization procedures are recommended for NSTEMI patients according to their clinical characteristics (Reed *et al*., 2017). As a result, biomarkers that can analyze and adapt a remedial timetable in AMI would be valuable. Cardiovascular troponin I (cTnI) and T (cTnT) are released by necrotic cardiomyocytes within 2 to 4 hours after a MI, peaking at 24 to 48 hours and lasting for up to a week, is currently the most widely used symptomatic biomarkers for AMI. As a result, it's difficult to tell the difference between small recurrent pockets of localized necrosis after the primary dead tissue. In this approach,

distinguishing biomarkers for early STEMI conclusion and studying the entire obsessive interplay of AMI is critical.

Talens *et al*. (2012) investigated the link between MI and DNA methylation at six loci thought to be sensitive to pre-birth nutrition as a marker of MI. Following that, the researchers discovered that the risk of MI in women is linked to DNA hypermethylation at specific INS and GNASAS loci (Talens *et al*., 2012). Furthermore, microarray analyses of entire genome DNA methylation using cases from the EPICOR study and EPIC-NL collaborator (Fiorito *et al*., 2014) identified a hypomethylated area in the zinc finger and BTB space containing protein 12 (ZBTB12) and LINE-1, implying that detailed methylation profiles in white platelets can be identified a few years before MI occurs. This results in a promising early MI biomarker (Guarrera *et al*., 2015). Hypermethylation of the aldehyde dehydrogenase two quality (ALDH2) advertiser, which has been linked to myocardial damage in animals after MI, is another scenario. ALDH2's cardio-defensive function is hampered by hypermethylation (Wang *et al*., 2015). Rask Andersen *et al*. (2016) conducted epigenome-wide association research to identify disease-specific changes in DNA methylation. The researchers discovered differences in DNA methylation at 211 CpG locations in persons with MI. Some of these locations were linked to cardiovascular capacity, CVD, cardiogenesis, and recovery from ischemic injury. Their findings include genes that may play a role in the pathophysiology of MI or healing (Rask-Andersen *et al*., 2016).

Similarly, in people who experienced a previous MI, genome-wide DNA methylation and quality philosophy evaluation of white platelets from a population-based study identified four differently methylated destinations. Surprisingly, they observed a link between platelet DNA methylation differences and the degrees of development separation factor 15 (GDF-15), which was overexpressed in MI patients' myocardium (Ek *et al*., 2016). Following that, a genome-wide DNA methylation analysis of entire blood tests from MI patients and controls identified two methylated areas in the zinc finger homeobox 3 (ZFHX3) and SWI/SNF-related, framework related, actin-subordinate controller of chromatin, subfamily a, part 4 (SMARCA4) genes that were independently linked to MI (Nakatochi *et al*., 2017).

Heart failure

Cardiovascular failure or breakdown is a chronic disorder in which the heart's ability to pump enough blood to the body to meet its needs is hampered. Hypertension, cardiomyopathy, MI, arrhythmias, and valvular diseases, to name a few, all contribute to cardiovascular collapse (Khatibzadeh *et al*., 2013). HF and epigenetic alterations are linked in several analytical reports. The heart and blood of patients with enlarged cardiomyopathy and healthy people were studied

for high-thickness epigenome-wide planning of DNA methylation. They saw several examples of epigenetic methylation protected via tissues—the CpGs districts identified as clever biomarkers of HF—and used this innovation to find epigenetic defenselessness and new biomarkers connected with HF and heart failure (Meder *et al*., 2017; Rau and Vondriska, 2017). In HF patients' blood leukocytes, differently methylation DNA areas were also identified (Li *et al*., 2017a). The discovery of unusual DNA methylation in the declaration of lymphocyte antigen 75 (LY75) and adenosine receptor A2A (ADORA2A) mRNA in idiopathic widened cardiomyopathy patients was linked to significant variations in the representation of lymphocyte antigen 75 (LY75) and adenosine receptor A2A (ADORA2A) mRNA (Haas *et al*., 2013). In neurotic and solid hearts, genome-wide guides of DNA methylation and increase of histone three lysine-36 trimethylations (H3K36me3) were also examined. Advertiser CpG islands, quality, intragenic CpG islands, and H3K36me3-rich regions of the genome all showed differences in DNA methylation. Advertisers of elevated traits had changed their DNA methylation, but not those of downregulated qualities. A large number of DUX4 records were linked to differences in DNA methylation and H3K36me3 augmentation. Although more research is needed, there is evidence that the epigenome may limit the declaration of essential features for the improvement of cardiomyopathies (Movassagh *et al*., 2011). In addition, there is an altered methylation design in the administrative areas of cardiovascular improvement qualities, such as T-box protein 5 (TBX5), heart and neural peak subsidiaries communicated 1 (HAND1), and NK2 homeobox 5 (NKX2.5) in patients with expanding cardiomyopathy (Jo *et al*., 2016). Koczor *et al*. (2013) examined distinct methylation patterns in patients with enlarged cardiomyopathy, characterized by congestive heart failure (HF). A computational analysis revealed that many great advertisers are differentially methylated (AURKB, BTNL9, CLDN5, and TK1). This study provides valuable information on DNA methylation and adjusted articulation in enlarged cardiomyopathy, which will aid treatment (Koczor *et al*., 2013).

Furthermore, in the murine model of pressure overburden, epigenetic alterations have been postulated to have a vital role in HF migration. The researchers discovered a drop in sarcoplasmic reticulum Ca ATPase (Atp2a2) levels as well as a compulsory enlistment of -myosin-weighty chain (Myh7) mRNA. Following two months of cross-over aortic tightness, they discovered H3K4me2, H3K9me2, H3K27me3, and H3K36me2, as well as a reduction in the lysine-explicit demethylase KDM2A. (Angrisano *et al*., 2014). Atp2a2 is a factor in heart capacity, and its decreased mobility is a common feature in HF. Gorski *et al*. (2019) investigated the significance of lysine acetylation in the function of Atp2a2 in HF patients. They discovered

that SIRT1 and Cap p300 regulate acetylation at lysine 492 and significantly reduce gene activity (Gorski *et al*., 2019). Combining all of this data would be critical in identifying anticipated biomarkers and new epigenetic medicines for HF treatment.

Surprisingly, reactivation of the fetal gene program in HF has been linked to epigenetic remodeling in the preliminary natriuretic peptide (ANP) and BNP promoters. HDAC4, which is sent out from the core, the nucleus, was upregulated in HF patients but not in response to an increase in histone acetylation.

Epigenetic Biomarkers: Limitations and Future Prospects

Epigenetic tools such as DNA methylation and histone changes have been identified as sources of potential biomarkers useful in therapeutic practice. Nonetheless, different epigenetic pathways lead to different CVDs, and different CVDs are regulated by the same epigenetic system, the great majority of which is still under investigation. In hypertension patients, hypermethylation of H3K79 (Rodriguez-Iturbe, 2006; Duarte *et al*., 2012) and ACE2 advertiser (Fan and al., 2017) has been shown. In addition, both mouse models of hypertension (Pojoga *et al*., 2011) and HF had hypermethylated H3K4 and H3K9 (Angrisano *et al*., 2014). This makes selecting and implementing some biomarkers for a given CVD difficult. Another potential concern is the type of the samples, particularly those obtained from pathology division assortments. These specimens are usually preserved in formaldehyde and paraffin, which debase DNA significantly. The length of fixation and storage determines the size, (Kristensen *et al*., 2009). As a result, a thorough examination of DNA's nature is required. However, in older samples, DNA methylation analysis can be done efficiently using polymerase chain reaction (PCR) techniques with small amplicons (Tournier *et al*., 2012; Wong *et al*., 2014). Change the convention with caution in certain situations. Consider that frozen and paraffin-saved samples may yield different results, and they should not be considered without careful consideration (Garca-Giménez *et al*., 2017).

It's critical to conduct studies with many collaborators in various independent research institutions, all using the same trial design, test arrangement, philosophy, and disease information. Before approving the outcomes of a more extensive sample study, small tolerant partners should be examined as pilot concentrates. The localization approach should be normalized for clinical use, and clinical preliminaries should be randomized and prepared. Compare and contrast the new biomarkers with the traditional biomarkers to determine their usefulness. Each biomarker's affectability and explicitness for a given condition must also be chosen (Engelhardt, 2012; Garca-Giménez *et al*., 2017). The luminometric methylation measure

and the methylation examination of CpG islands in repeatable components (LINE-1) are widely used techniques for locating DNA methylation. Even though the estimations obtained using the two procedures have a clear relationship, the correlation isn't recommended because a reliable inclination between the outcomes has been exhibited (Knothe *et al*., 2016). Surprisingly, a significant multicenter investigation comparing possible and routine clinical use of DNA methylation measurements has been conducted. According to the authors, there is a considerable deal of agreement between DNA methylation tests, which may be carried out in a wide range of approval scenarios, the development of new biomarkers, and clinical diagnostics (Outline Consortium, 2016).

Conclusion

Epigenetics and its dynamic cross-talk with inherited traits have received a lot of attention in recent years. Providing a tailored epigenetic example can provide a wealth of information on epigenetic machinery that can be used to customize CVD diagnosis and treatment strategies. DNA methylation, which is regulated by DNA methyltransferases, is often linked to transcriptional restriction, affecting gene articulation by altering the DNA promoter's accessibility to RNA polymerase and consequently gene transcription.

Recent advancements in innovation and data analysis have made it possible to create point-by-point epigenetic maps, which could be used as another tool in clinical practice to assess cardiovascular risk and risk drivers. Epigenetic data can also aid in the prediction of specific drug effects. Crucially, DNA methylation is gaining traction among mainstream academics as a tool for predicting and predicting CVDs. Nonetheless, because of flaws in explicit analytic biomarkers, verification of the current findings is required, with many exploratory communities and large sample size. This will be completed in its entirety.

Acknowledgement

The authors would like to acknowledge The Pan Africa Research Group (PARG) for providing the platform for the conduct of this research. Special acknowledgment also goes to the Director, Chima Cyril Hampo and team leaders, Abolaji S. Olagunju, Akinwale Faniyi and the entire executives of the group, for their instrumental efforts in ensuring that this research had a successful outcome.

Conflict of interest

Authors declared no conflict of interest for this article

Funding

The article did not receive any form of funding from any organization.

REFERENCES

Adachi T., Nakanishi M., Otsuka Y., Nishimura K., Hirokawa G., Goto Y., et al. (2010). Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin. Chem. 56, 1183–1185. 10.1373/clinchem.2010.144121.

Ai J., Zhang R., Li Y., Pu J., Lu Y., Jiao J., et al. (2010). Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun. 391, 73–77. 10.1016/j.bbrc.2009.11.005.

Akat K. M., Moore-McGriff D., Morozov P., Brown M., Gogakos T., Correa Da Rosa J., et al. (2014). Comparative RNAsequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers.Proc. Natl. Acad. Sci. U. S. A 111, 11151–11156. 10.1073/pnas.1401724111.

Akhtar M. M., Micolucci L., Islam M. S., Olivieri F., Procopio A. D. (2016). Bioinformatic tools for microRNA dissection. Nucleic Acids Res. 44, 24–44. 10.1093/nar/gkv1221.

Alavi-Moghaddam M., Chehrazi M., Alipoor S. D., Mohammadi M., Baratloo A., Mahjoub M. P., et al. (2018). A preliminary study of microRNA-208b after acute myocardial infarction: impact on 6-month survival. Dis. Markers 2018, 2410451–7. 10.1155/2018/2410451.

Alikhani-Koopaei R., Fouladkou F., Frey F. J., Frey B. M. (2004). Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J. Clin. Investig. 114, 1146–1157. 10.1172/JCI21647.

Angrisano T., Schiattarella G. G., Keller S., Pironti G., Florio E., Magliulo F., et al. (2014). Epigenetic switch at atp2a2 and myh7 gene promoters in pressure overload-induced heart failure. PLoS One 9, e106024. 10.1371/journal.pone.0106024.

Authors/Task Force members. Windecker S., Kolh P., Alfonso F., Collet J.-P., Cremer J., et al. (2014). 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35, 2541–2619. 10.1093/eurheartj/ehu278

Babuin L., Jaffe A. S. (2005). Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 173, 1191–1202. 10.1503/cmaj/051291

Baccarelli A., Rienstra M., Benjamin E. J. (2010). Cardiovascular epigenetics: basic concepts and results from animal and human studies. Circ. Cardiovasc. Genet. 3, 567–573. 10.1161/CIRCGENETICS.110.958744

Baptista R., Marques C., Catarino S., Enguita F. J., Costa M. C., Matafome P., et al. (2018). MicroRNA-424(322) as a new marker of disease progression in pulmonary arterial hypertension and its role in right ventricular hypertrophy by targeting SMURF1. Cardiovasc. Res. 114, 53–64. 10.1093/cvr/cvx187

Bartel D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233. 10.1016/j.cell.2009.01.002

Bauters C., Kumarswamy R., Holzmann A., Bretthauer J., Anker S. D., Pinet F., et al. (2013). Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int. J. Cardiol. 168, 1837–1840. 10.1016/j.ijcard.2012.12.074

Bayés-Genis A., Lanfear D. E., de Ronde M. W. J., Lupón J., Leenders J. J., Liu Z., et al. (2018). Prognostic value of circulating microRNAs on heart failure–related morbidity and mortality in two large diverse cohorts of general heart failure patients. Eur. J. Heart Fail. 20, 67–75.

Beaumont J., López B., Ravassa S., Hermida N., José G. S., Gallego I., et al. (2017). MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. Sci. Rep. 7, 40696.

Beekman M., Nederstigt C., Suchiman H. E. D., Kremer D., van der Breggen R., Lakenberg N., et al. (2010). Genome-wide association study (GWAS)–identified disease risk alleles do not compromise human longevity. Proc. Natl. Acad. Sci. U. S. A 107, 18046–18049.

Beg F., Wang R., Saeed Z., Devaraj S., Masoor K., Nakshatri H. (2017). Inflammation-associated microRNA changes in circulating exosomes of heart failure patients. BMC Res. Notes 10, 751.

Bekkering S., van den Munckhof I., Nielen T., Lamfers E., Dinarello C., Rutten J., et al. (2016). Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans *in vivo* .Atherosclerosis 254, 228–236.

Białek S., Górko D., Zajkowska A., Kołtowski Ł., Grabowski M., Stachurska A., et al. (2015). Release kinetics of circulating miRNA-208a in the early phase of myocardial infarction. Kardiologia Polska 73, 613–619.

Bildirici A. E., Arslan S., Özbilüm Şahin N., Berkan Ö., Beton O., Yilmaz M. B. (2018). MicroRNA-221/222 expression inatherosclerotic coronary artery plaque versus internal mammarian artery and in peripheral blood samples. Biomarkers 23, 670–675.

BLUEPRINT Consortium (2016). Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. Nat. Biotechnol. 34, 726–737.

Bogdarina I., Welham S., King P. J., Burns S. P., Clark A. J. L. (2007). Epigenetic modification of the renin–angiotensin system in the fetal programming of hypertension. Circ. Res. 100, 520–526.

Bye A., Røsjø H., Nauman J., Silva G. J. J., Follestad T., Omland T., et al. (2016). Circulating microRNAs predict future fatal myocardial infarction in healthy individuals—the HUNT study. J. Mol. Cell Cardiol. 97, 162–168.

Cakmak H. A., Coskunpinar E., Ikitimur B., Barman H. A., Karadag B., Tiryakioglu N. O., et al. (2015). The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome-wide expression study. J. Cardiovasc. Med. (Hagerstown) 16, 431–437.

Cao J., Yan Q. (2012). Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. Front. Oncol. 2, 26.

Charrier H., Cuvelliez M., Dubois-Deruy E., Mulder P., Richard V., Bauters C., et al. (2019). Integrative system biology analyses identify seven microRNAs to predict heart failure. Noncoding RNA 5, E22–E30.

Chelbi S. T., Mondon F., Jammes H., Buffat C., Mignot T.-M., Tost J., et al. (2007). Expressional and epigenetic alterations of placental serine protease inhibitors: SERPINA3 is a potential marker of preeclampsia. Hypertension 49, 76–83.

Chen F., Yang J., Li Y., Wang H. (2018. a). Circulating microRNAs as novel biomarkers for heart failure. Hellenic J. Cardiol. 59, 209–214.

Chen J., Xu L., Hu Q., Yang S., Zhang B., Jiang H. (2015. a). MiR-17-5p as circulating biomarkers for the severity of coronary atherosclerosis in coronary artery disease. Int. J. Cardiol. 197, 123–124.

Chen M.-C., Chang T.-H., Chang J.-P., Huang H.-D., Ho W.-C., Lin Y.-S., et al. (2016). Circulating miR-148b-3p and miR-409- 3p as biomarkers for heart failure in patients with mitral regurgitation. Int. J. Cardiol. 222, 148–154.

Chen S., Chen R., Zhang T., Lin S., Chen Z., Zhao B., et al. (2018. b). Relationship of cardiovascular disease risk factors and noncoding RNAs with hypertension: a case-control study. BMC Cardiovasc. Disord. 18, 58.

Chen W., Li S. (2017). Circulating microRNA as a novel biomarker for pulmonary arterial hypertension due to congenital heart disease. Pediatr. Cardiol. 38, 86–94.

Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997–1006.

Chen X., Zhang L., Su T., Li H., Huang Q., Wu D., et al. (2015. b). Kinetics of plasma microRNA-499 expression in acute myocardial infarction. J. Thorac. Dis. 7, 890–896.

Cheng C., Wang Q., You W., Chen M., Xia J. (2014). MiRNAs as biomarkers of myocardial infarction: a meta-analysis. PLoS ONE 9, e88566.

Cho H.-M., Lee H.-A., Kim H. Y., Han H. S., Kim I. K. (2011). Expression of Na+-K+ -2Cl- cotransporter 1 is epigenetically regulated during postnatal development of hypertension. Am. J. Hypertens. 24, 1286–1293.

Choi J.-H., Nam K.-H., Kim J., Baek M. W., Park J.-E., Park H.-Y., et al. (2005). Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biol. 25, 2404–2409.

Choi S. Y., Yun J., Lee O. J., Han H. S., Yeo M. K., Lee M. A., et al. (2013). MicroRNA expression profiles in placenta withsevere preeclampsia using a PNA-based microarray. Placenta 34, 799–804.

Cortez-Dias N., Costa M. C., Carrilho-Ferreira P., Silva D., Jorge C., Calisto C., et al. (2016). Circulating miR-122-5p/miR- 133b ratio is a specific early prognostic biomarker in acute myocardial infarction. Circ. J. 80, 2183–2191.

Coskunpinar E., Cakmak H. A., Kalkan A. K., Tiryakioglu N. O., Erturk M., Ongen Z. (2016). Circulating miR-221-3p as a novel marker for early prediction of acute myocardial infarction.

Gillette TG, & Hill JA (2015). Readers, writers, and erasers: chromatin as the whiteboard of heart disease. *Circ Res*, 116, 1245–1253. [PMC free article] [PubMed] [Google Scholar]

Jeltsch A, & Jurkowska RZ (2014). New concepts in DNA methylation. *Trends Biochem Sci*, 39, 310–318. [PubMed] [Google Scholar]

Raghuraman S., Donkin I., Versteyhe S., Barrès R., Simar D. The emerging role of epigenetics in inflammation and immunometabolism. *Trends in Endocrinology & Metabolism.* 2016;27(11):782–795.doi:10.1016/j.tem.2016.06.008. [PubMed]
[CrossRef] [Google Scholar]

Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, et al. Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation.* 2006;113:e85–151. [PubMed] [Google Scholar]

Yang Y, Hsu PJ, Chen YS, & Yang YG (2018). Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. *Cell Res*, 28, 616–624. [PMC free article] [PubMed] [Google Scholar]

Yang Y, Li X, Peng L, An L, Sun N, Hu X, Zhou P, Xu Y, Li P, & Chen J (2018). Tanshindiol C inhibits oxidized low-density lipoprotein induced macrophage foam cell formation via a peroxiredoxin 1 dependent pathway. *Biochim Biophys Acta*, 1864, 882–890. [PubMed] [Google Scholar]